Clinical Trial Search

Primary: Percentage of Participants Achieving DAS28 Low Disease Activity at Week 12 — 21.2; 33.0 percentage of participants — p=0.055

Primary: Event Rate for a Cardiovascular Composite of Incident Myocardial Infarction, Stroke, or Heart Failure — 10.62; 8.13 Events per 1000 person years

Primary: Mean 48-week Change in DAS28 — -2.12; -2.29 units on a scale

Primary: 12 Month Change in 7-Joint Ultrasound (US) Inflammatory Score — 11.4 units on a scale — p=<0.01

Primary: Disease Activity Score Based on 28-joint Disease Activity Score (DAS28) — 4.40; 4.03; 4.57; 4.48 units on a scale

Primary: Alteration of Microbiota, Alteration of T Cell Function/Activation — 4; 10; 2; 0 participants

Primary: Metabolic Syndrome Severity Z-score (MSSc) — -1.89; -1.82; -3.23; -3.49 Z-score (unitless) — p=<0.05

Primary: Evaluation of Disease Duration: Time From Diagnosis to Disease-Modifying Anti-Rheumatic Drug Treatment in Rheumatoid Arthritis — 11.7177 Months

Primary: Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Synovitis Score — 3.4; 2.3…

Primary: Primary: Participants With EULAR (Good) — 19 participants

Primary: Clinical Disease Activity Index (CDAI) Remission (≤2.8) at Both Week 20 and Week 24 — 18.8; 6.1 percentage of subjects

Primary: DAS28-ESR — 3.75; 3.72; 3.59; 3.69 units on a scale — p=0.82

Primary: Number of Participants With a Diagnosis of Rheumatoid Arthritis (RA) by American Rheumatism Association (ARA) Criteria and/or Discontinued Due to Lack of Efficacy — 12…

Primary: Number of Participants in DAS 28 C-reactive Protein (CRP) Remission at Month 12 — 106; 59 participants — p=<0.001

Primary: Change From Baseline in Joint Status Assessed by Radiographic (Roentgen) Progression — 6.9; 24.3; 0.0; 0.3 scores on a scale

Primary: Low Synovitis Scores — 1 Participants

Primary: Number of Participants That Met Sustained Remission at Week 76 and Week 91 Based on DAS28 Score — 40; 26; 15 Participants — p=<0.0001

Primary: Disease Activity Score Erythrocyte Sedimentation Rate(DAS28-ESR) — 3.0; 2.9; 3.1; 2.8 Scores on a scale

Primary: Change in Diffusion Capacity for Carbon Monoxide (DLco) From Baseline to 48 Weeks — 4; 2; 1 participants

Primary: Number of Subjects With Lipids Checked (Available Now Through National Laboratory Chain) or That Reported Having Their Lipids Checked by Their 1-week or 3-month Visit…

Primary: Percentage of Subjects Reporting At Least One Treatment-emergent Adverse Event (TEAE) During The Study Period — 70.8 percentage of participants

Primary: RADAI Disease Activity Score — -0.4; 0.1 units on a scale — p=0.04

Primary: Disease Activity — 3.38; 3.62 score on a scale

Primary: CDAI Score — 36.06 score on a scale

Primary: Percentage of Participants in Simple Disease Activity Index (SDAI) Remission at Week 24 — 21.3; 16.0 Percentage of participants — p=0.2359

Primary: Percentage of CD27+ Switched Memory B Cells at Week 12 — 13.2; 13.8 Percentage of B Cells — p=0.3

Primary: ACR Efficacy Criteria — 63; 57; 57; 61 participants

Primary: Percentage of Adverse Events (AEs) — 55.0; 70.0; 57.9 Percentage of participant with AEs

Primary: Mean Change From Baseline in Global Power Doppler Ultrasonography (PDUS) Score Assessing the Metacarpophalangeal (MCP) 2-5 Joints of Both Hands (LOCF Analysis) — -0.7…

Primary: Percentage of Participants With a Disease Activity Score 28 (DAS28) Remission Response at Week 24 — 15.0; 31.9; 44.8; 38.7 Percentage of participants — p=<0.0001